Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 41.8 14.5 288.0% View Chart
P/BV x 2.5 1.4 175.8% View Chart
Dividend Yield % 2.1 1.5 142.3%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-21
AUROBINDO PHARMA
Mar-22
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1501,064 108.1%   
Low Rs527584 90.2%   
Sales per share (Unadj.) Rs274.4400.3 68.5%  
Earnings per share (Unadj.) Rs56.745.7 124.1%  
Cash flow per share (Unadj.) Rs66.064.9 101.7%  
Dividends per share (Unadj.) Rs14.009.00 155.6%  
Avg Dividend yield %1.71.1 152.9%  
Book value per share (Unadj.) Rs260.9419.4 62.2%  
Shares outstanding (eoy) m196.56585.94 33.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.12.1 148.5%   
Avg P/E ratio x14.818.0 82.0%  
P/CF ratio (eoy) x12.712.7 100.1%  
Price / Book Value ratio x3.22.0 163.6%  
Dividend payout %24.719.7 125.4%   
Avg Mkt Cap Rs m164,818482,799 34.1%   
No. of employees `000NANA-   
Total wages/salary Rs m10,51234,509 30.5%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m53,931234,555 23.0%  
Other income Rs m8753,226 27.1%   
Total revenues Rs m54,806237,781 23.0%   
Gross profit Rs m14,80142,566 34.8%  
Depreciation Rs m1,83511,265 16.3%   
Interest Rs m160486 32.9%   
Profit before tax Rs m13,68134,040 40.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5337,256 34.9%   
Profit after tax Rs m11,14826,784 41.6%  
Gross profit margin %27.418.1 151.2%  
Effective tax rate %18.521.3 86.9%   
Net profit margin %20.711.4 181.0%  
BALANCE SHEET DATA
Current assets Rs m25,779181,227 14.2%   
Current liabilities Rs m12,80881,560 15.7%   
Net working cap to sales %24.142.5 56.6%  
Current ratio x2.02.2 90.6%  
Inventory Days Days2325 93.8%  
Debtors Days Days262 3.8%  
Net fixed assets Rs m41,311155,104 26.6%   
Share capital Rs m393586 67.1%   
"Free" reserves Rs m50,883245,174 20.8%   
Net worth Rs m51,276245,760 20.9%   
Long term debt Rs m1,9992,492 80.2%   
Total assets Rs m67,090336,331 19.9%  
Interest coverage x86.471.0 121.7%   
Debt to equity ratio x00 384.4%  
Sales to assets ratio x0.80.7 115.3%   
Return on assets %16.98.1 207.9%  
Return on equity %21.710.9 199.5%  
Return on capital %26.013.9 186.8%  
Exports to sales %66.831.1 215.0%   
Imports to sales %12.711.9 106.5%   
Exports (fob) Rs m36,02072,862 49.4%   
Imports (cif) Rs m6,84527,965 24.5%   
Fx inflow Rs m36,02077,245 46.6%   
Fx outflow Rs m6,84531,524 21.7%   
Net fx Rs m29,17545,721 63.8%   
CASH FLOW
From Operations Rs m14,63450,165 29.2%  
From Investments Rs m-8,388-32,116 26.1%  
From Financial Activity Rs m-5,974-29,693 20.1%  
Net Cashflow Rs m262-11,674 -2.2%  

Share Holding

Indian Promoters % 69.1 48.8 141.7%  
Foreign collaborators % 0.5 3.1 16.6%  
Indian inst/Mut Fund % 18.1 38.0 47.6%  
FIIs % 5.9 20.7 28.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 48.2 63.1%  
Shareholders   101,457 359,684 28.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SUN PHARMA    DR. REDDYS LAB    LUPIN    CIPLA    ZYDUS LIFESCIENCES    



Today's Market

SGX Nifty Trades Flat, Adani Enters Alumina and Iron Ore Business, ICICI Bank Hits Rs 6-tn in Market Cap, and Top Buzzing Stocks Today(Pre-Open)

On Thursday, Indian share markets rose tracking the rally in US stocks after softer-than-expected US inflation data stoked speculation the Federal Reserve could pivot to a shallower pace of interest-rate hikes.